Research progress in epigenetic regulation of myocardial ischemia/reperfusion injury by traditional Chinese medicine
10.16438/j.0513-4870.2015-1037
- VernacularTitle:基于表观遗传学调控的中医药防治心肌缺血再灌注损伤的研究进展
- Author:
Guang LI
1
;
Xiao-yan XING
1
;
Mei-shuang ZHANG
2
;
Xue-hong DENG
1
;
Shi-min TANG
2
;
Na-na ZHAO
2
;
Gui-bo SUN
1
;
Xiao-bo SUN
1
Author Information
1. Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing 100093, China
2. Changchun University of Chinese Medicine, Changchun 130117, China
- Publication Type:REVIEWS
- Keywords:
epigenetic;
reperfusion injury;
traditional Chinese medicine;
DNA methylation;
histone code;
miRNA
- From:
Acta Pharmaceutica Sinica
2016;51(7):1047-
- CountryChina
- Language:Chinese
-
Abstract:
Epigenetic is a hotspot of post-genomic era research, and epigenetic modification is a mechanism in the study of cardiovascular disease. Myocardial ischemia-reperfusion injury (MIRI) is one of the problems in the cardiovascular disease, and many experimental interventions are reported in the protection of the ischemic myocardium in experimental animals. However, with the exception of early reperfusion, none has been translated into clinical practice. There is an advantage of traditional Chinese medicine (TCM) in the regulation of epigenetic modification, and pathogenesis of myocardial ischemia-reperfusion injury. This review article is prepared to cover the research progress in the treatment of myocardial ischemia-reperfusion injury by TCM with a focus on epigenetic regulation. The epigenetic regulation is documented in TCM theory through a systematic review of the protecting drugs in the MIRI development guidelines.
